Dexmedetomidine by Teikoku Pharma USA for Post-Operative Pain: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexmedetomidine overview

Dexmedetomidine (TPU-006) is under development for the treatment of chronic pain and post-operative pain in hallux valgus (Bunion). The drug candidate is formulated as a 3 days patch and administered through transdermal route. It acts by targeting selective alpha 2 adrenergic receptors. The drug candidate is developed based on Matrix patch technology.

Teikoku Pharma USA overview

Teikoku Pharma USA (Teikoku Pharma), a subsidiary of Teikoku Seiyaku Co Ltd, s a specialty pharmaceutical company that develops and manufactures pharmaceutical products based on its delivery platform technologies in the therapeutic areas of CNS, pain management and oncology. The company offers products such as lidoderm, a prescription, topical, hydrogel patch for post-herpetic neuralgia (PHN) and also provides analgesia directly to the affected nerves. Teikoku Pharma’s versatis is used for the management of neuropathic pain associated with previous herpes zoster infection. The company also offers non-alcohol docetaxel injections used for the treatment of non-small cell lung cancer, breast cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. Its pipeline products include rasagiline patch (TPU-002) for parkinson’s disease, TPU-010 indicated for puritis and a dexmedetomidine patch (TPU-006) for pain management. Teikoku Pharma is headquartered in San Jose, California, the US.

For a complete picture of Dexmedetomidine’s drug-specific PTSR and LoA scores, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.